BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase III (World)
RedHill Biopharma Ltd. (RDHL) Provides Update On Expansion Of Ongoing RHB-105 Phase 3 Study, Targeting Broadened H. Pylori Indication Authorized By FDA 8/27/2014
Regeneron Pharmaceuticals, Inc. (REGN) And Sanofi (France) (SAN.PA) To Present Results From Four Phase 3 Alirocumab Trials In Hot Line Session At ESC Congress 2014 8/25/2014
AstraZeneca PLC (AZN) Starts Late-Stage Asthma Drug Trial 8/14/2014
Mologen AG (MOLGF.PK): Preparation And Launch Of New Studies Characterized The First Half-Year 2014 8/13/2014
AstraZeneca PLC (AZN) Gets A Pipeline Boost From Good Phase 3 Gout Drug Results 8/13/2014
Cortendo AB: First Patient Enrolled Into Normocort Phase 3 SONICS Trial Following A Successful EU Investigator Meeting 8/12/2014
Novartis AG (NVS) To Tout Heart Failure Data At European Society of Cardiology Congress 2014 8/12/2014
Genmab A/S (GEN.CO) Announces New Phase 3 Study Of Daratumumab In Front Line Multiple Myeloma 8/11/2014
New Data Shows High Efficacy For Can-Fite BioPharma (CFBI)'s CF101 In Rheumatoid Arthritis And Psoriasis Patients 8/6/2014
Hope Builds For New Novartis AG (NVS) Heart Failure Drug LCZ696 8/5/2014
Genmab A/S (GEN.CO), GlaxoSmithKline (GSK)'s Ofatumumab Meets Primary Endpoint In Late-Stage Study 8/1/2014
Alkermes plc (ALKS) Announces Initiation Of FORWARD-5 Clinical Study Of ALKS 5461 For Treatment Of Major Depressive Disorder 7/30/2014
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Drug Alirocumab Cuts Cholesterol In Nine Late-Stage Trials 7/30/2014
Genmab A/S (GEN.CO) Announces Phase 3 Study Of Daratumumab In Front Line Multiple Myeloma 7/18/2014
TauRx Therapeutics Achieves Enrollment Target In The First Of Its Two Phase III Clinical Trials Of LMTX™ In Alzheimer's Disease 7/17/2014
Basilea Pharmaceutica (BSLN.SW) Reports That Isavuconazole Receives Orphan Drug Designations In Europe For The Treatment Of Invasive Mold Infections 7/14/2014
Alcobra (ADHD) Completes Patient Recruitment In Phase 3 Clinical Trial Of MDX In Adult ADHD 7/14/2014
FDA Green Lights Starpharma Holdings Ltd's VivaGel Trial Design 7/14/2014
Astellas Pharma Inc. (ALPMY) Details Pipeline Progress At R&D Meeting 7/11/2014
Helsinn Announces That Phase 2/3 Pivotal Trials For NEPA (Netupitant 300 Mg + Oral Palonosetron 0.50 Mg), Will Be Published In The Annals Of Oncology 7/10/2014
CEL-SCI (CVM) Receives Regulatory Clearance To Expand CEL-SCI’S Phase 3 Head And Neck Cancer Trial Into Austria 7/8/2014
Endo International plc (ENDP), BioDelivery Sciences International (BDSI) Painkiller BEMA® Buprenorphine Effective In Phase 3 Study 7/7/2014
Bayer Inc. Release: Nexavar® (sorafenib tablets) Now Approved In Canada For The Treatment Of Differentiated Thyroid Cancer 7/7/2014
GlaxoSmithKline (GSK), Genmab A/S (GEN.CO) Leukemia Drug Ofatumumab Fails To Meet Main Trial Goal 7/2/2014
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus® XR Demonstrates Lower Treatment Failure Rate In African-Americans Compared To Twice-Daily Tacrolimus (Prograf®) 6/30/2014
Protalix Biotherapeutics, Inc. (PLX) Announces New Data On ELELYSO™ (Taliglucerase Alfa) Presented At The European Working Group On Gaucher Disease 2014 11th Meeting 6/27/2014
H. Lundbeck A/S (LUN.CO)'s Late Stage Trials For Stroke Failed To Meet Primary Endpoint 6/27/2014
Eisai Inc. (ESALF.PK) & Helsinn Group To Present New CINV Research At 2014 International Symposium On Supportive Care In Cancer 6/26/2014
FDA Requests More Data For Basilea Pharmaceutica (BSLN.SW)'s Pneumonia Drug Ceftobiprole; Stock Drops -8.15% At Market Close (June 25, 2014) 6/25/2014
Orexo AB (ORXOF) Release: Top-Line Data From A Phase 3 Clinical Trial Demonstrates That Zubsolv® Is As Effective As Suboxone® Film In The Treatment Of Opioid Dependence 6/25/2014
Agreement On Phase 3 Trial Protocol Of OSE Pharma's OSE-2101 From The FDA And European Medicines Agency 6/24/2014
Positive New Phase 3a Data On Novo Nordisk A/S (NVO)'s Liraglutide 6/23/2014
Orexo AB (ORXOF) Release: Positive Top-Line Results From Two Phase 3 Clinical Trials That Assessed Zubsolv® For Induction Of Buprenorphine Maintenance Therapy 6/23/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Positive Two-Year Results From Pivotal Phase 3 Study Of Envarsus® XR (Tacrolimus Extended-Release Tablets) In De Novo Kidney Transplant Patients 6/23/2014
Boehringer Ingelheim (Canada) Ltd. Release: Study Findings Show Tiotropium Respimat®* Well-Tolerated And Effective In Japanese Patients With Symptomatic Asthma 6/19/2014
Successful Phase 3 Results For Alkermes plc (ALKS)'s Schizophrenia Drug Aripiprazole Lauroxil 6/19/2014
Actelion Ltd. (ALIOF.PK) Soars As Heart-Lung Drug Selexipag Meets Main Goal In Late-Stage Study 6/18/2014
Biogen Idec, Inc. (Massachusetts) (BIIB), AbbVie (ABBV)'s Once-A-Month Drug Daclizumab Slows Multiple Sclerosis Episodes, Safety Issues Reoccur 6/17/2014
Novo Nordisk A/S (NVO)'s Big-Selling Diabetes Drug Victoza Appears Effective For Weight Loss 6/16/2014
Sanofi (France) (SAN.PA) Toujeo Shows Great Promise As Lantus Successor 6/16/2014
Novo Nordisk A/S (NVO) Combination Diabetes Drug IDegLira Effective After 1 Year Study 6/16/2014
Eli Lilly and Company (LLY) Release: Type 2 Diabetes: Jardiance® (Empagliflozin) As An Add-On Therapy Significantly Reduced Blood Glucose And Body Weight In Two Newly Presented Phase 3 Trials 6/16/2014
Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Tout Positive Phase 3 Data For Rheumatoid Drug Sarilumab 6/13/2014
All Eyes Are On AstraZeneca PLC (AZN) As Its Diabetes Drugs Go Under The Spotlight At Major Scientific Meeting 6/12/2014
Vertex Pharmaceuticals (MA) (VRTX) Announces Presentation Of New KALYDECO™ (Ivacaftor) Data At European Cystic Fibrosis Society Conference 6/12/2014
GlaxoSmithKline (GSK), Theravance, Inc. (THRX) Put Out Positive Update On Two Phase 3 Ellipta COPD Studies 6/11/2014
EULAR: Romosozumab Significantly Increases Bone Mineral Density And Bone Content Compared With Teriparatide 6/11/2014
Pfizer Inc. (PFE) To Showcase Over 10 Abstracts For XELJANZ® At Major Conference 6/11/2014
Northwest Biotherapeutics (NWBO) Release: DCVAX®-L Phase 3 Trial Initiated In Germany 6/10/2014
ALK-Abello A/S Presents Phase 3 Data On House Dust Mite SLIT-Tablet At EAACI Annual Congress In Copenhagen 6/9/2014
GlaxoSmithKline (GSK) Launches Huge Phase 3 Study For Heart Drug Losmapimod 6/9/2014
GW Pharmaceuticals Announces Epidiolex® Receives Fast Track Designation From FDA For The Treatment Of Dravet Syndrome 6/6/2014
RedHill Biopharma Ltd. (RDHL) Announces New RHB-104 Patent In Japan And Provides Update On Phase 3 Crohn's Program 6/5/2014
Jiangsu Hengrui Medicine Co. Ltd. Reports Positive Phase 3 Data For Cancer Drug 6/4/2014
Dainippon Sumitomo Pharma Co., Ltd. Halts Key Phase 3 Global Colorectal Carcinoma Monotherapy Trial 5/28/2014
RedHill Biopharma Ltd. (RDHL) Announces FDA Clearance For Phase 3 Study With RHB-102 Planned To Commence In Q3/2014 5/22/2014
Santhera Pharmaceuticals AG (SANN.SW) Reports Positive Outcome For Catena®/Raxone® In Phase 3 DMD Trial Supported By Additional Respiratory Function Data 5/22/2014
SOTIO Initiates VIABLE, A Global Phase 3 Clinical Trial For Prostate Cancer Immunotherapy Treatment With DCVAC/PCa 5/22/2014
Boehringer Ingelheim Corporation Stakes Claim To Combination COPD Market As Phase 3 Data For Tiotropium Is Positive 5/22/2014
RedHill Biopharma Ltd. (RDHL) And IntelGenx Corp. Report Positive RHB-103 Bioavailability Study Results In Support Of Planned European Marketing Application In Q3/2014 5/21/2014
GlaxoSmithKline (GSK), Genmab A/S (GEN.CO)' Arzerra Fails Phase 3 Lymphoma Trial 5/21/2014
Kamada Ltd. (KMDA) Crashes After Key Trial Failure 5/19/2014
In The Battle Of Idiopathic Pulmonary Fibrosis Drugs, Boehringer Ingelheim Corporation's Nintedanib Wows In Phase 3 Trial 5/19/2014
Basilea Pharmaceutica (BSLN.SW) Reports Additional Data On Positive Isavuconazole Phase 3 SECURE Study At ECCMID 5/14/2014
Mologen AG (MOLGF.PK): Development Of Main Product Candidate Pushed Forward Swiftly In First Quarter 5/14/2014
Santhera Pharmaceuticals AG (SANN.SW) Announces Successful Outcome Of Phase 3 Study With Catena®/Raxone® In Duchenne Muscular Dystrophy 5/14/2014
Gene Signal Announces Positive Data From Phase 3 Trial of Aganirsen Eye Drops For Corneal Neovascularisation Due To Inflammation, A Rare Eye Disease With European Orphan Drug Designation 5/14/2014
GlaxoSmithKline (GSK)'s Once Promising Heart Drug Strikes Out Again 5/14/2014
Amgen (AMGN), AstraZeneca PLC (AZN)'s Psoriasis Drug Brodalumab Meets Goals In Phase 3 Study 5/14/2014
Taiho Oncology's TAS-102 Meets Primary Endpoint Of Improving Overall Survival In Global Phase 3 RECOURSE Trial In Refractory Metastatic Colorectal Cancer 5/12/2014
AstraZeneca PLC (AZN) Jumps Start Late-Stage Study Of Key New Cancer Drug 5/9/2014
Immune Pharmaceuticals, Inc. Announces Phase 3 Development And Commercialization Strategy For AMIKET 5/5/2014
Endocyte, Inc. (ECYT), Merck & Co., Inc. (MRK) Halt Study Of Ovarian Cancer Drug Vintafolide; Endocyte Stock Plunges -61.91% At Market Close (May 2, 2014) 5/2/2014
Teva Pharmaceutical Industries Limited (TEVA) Reports Positive Results From Pivotal Phase 3 Study To Evaluate Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) For Moderate To Severe Chronic Low Back Pain 4/30/2014
RedHill Biopharma Ltd. (RDHL) Reports Successful RHB-102 Bioavailability Clinical Trial And Planned Submission Of European Marketing Application In Q3/2014 4/30/2014
OncoGenex Pharmaceuticals Inc. (OGXI)'s Long Awaited Cancer Drug Ends With A Phase 3 Stumble; Stock Down -60.31% At Market Close (April 28, 2014) 4/30/2014
Cell Therapeutics, Inc. (CTIC) PIXUVRI® Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma 4/29/2014
GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA In Cancer Pain 4/28/2014
IntelGenx Corp. And RedHill Biopharma Ltd. (RDHL) Announce Commencement Of A Bioavailability Study With Anti-Migraine Versafilm™ Product To Support European Marketing Application Planned For Q3/2014 4/28/2014
Merck & Co., Inc. (MRK) Announces Positive Outcome Of 3b Study For Kuvan 4/24/2014
Boehringer Ingelheim Corporation Rethinks Hepatitis Business, Braces For A Rough 2014 4/17/2014
AbbVie (ABBV)'s Experimental Hepatitis C Regimen Associated With High Cure Rates In Late-Stage Studies 4/15/2014
BioAlliance Pharma Announces A New Positive DSMB Recommendation To Continue Its Phase III Clinical Trial With Livatag® In Primary Liver Cancer 4/14/2014
BioAlliance Pharma Announces A New Positive DSMB Recommendation To Continue Its Phase 3 Clinical Trial With Livatag® In Primary Liver Cancer 4/14/2014
Biogen Idec, Inc. (Massachusetts) (BIIB)'s Blood Disorder Drug Succeeds In Phase 3 Trial 4/10/2014
Alkermes plc (ALKS) Pulls Off Phase 3 Win for Long-Lasting Schizophrenia Drug 4/9/2014
GlaxoSmithKline (GSK) Halts Late-Stage Lung Cancer Vaccine Trial 4/3/2014
Medivir AB (MVRBF) Release: Two Phase 3 Trials Evaluating Once-Daily Simeprevir And Sofosbuvir In Hepatitis C Infected Patients Have Been Initiated 4/2/2014
Novartis AG (NVS) Closes Heart Drug Study Early After Strong Results 4/1/2014
Novartis AG (NVS)'s Rare Lung Cancer Drug Ceritinib Shows Positive Response In Study 3/27/2014
Swedish Orphan Biovitrum Release: Kiobrina Pivotal Phase 3 Study Did Not Meet Primary Endpoint 3/26/2014
CogState Ltd (CGS.AX)'s Technology Chosen For Major Phase 3 Trial Of Alzheimer's Disease Drug 3/25/2014
Novo Nordisk A/S (NVO) Reports Positive Results From First Phase 3 Trial With N8-GP, A Long-Acting Factor VIII For Treatment Of Haemophilia A 3/19/2014
Alcobra (ADHD) Announces Enrollment Of First Patient In Phase 3 Clinical Trial For MDX In Adult ADHD 3/18/2014
GlaxoSmithKline (GSK), Theravance, Inc. (THRX) Touts Positive Results From Three COPD Phase 3 Studies 3/17/2014
Medivir AB (MVRBF) Release: New Phase 3 Data From Once-Daily Simeprevir Presented At The Conference Of The Asian Pacific Association For The Study Of The Liver (APASL) 3/17/2014
GlaxoSmithKline (GSK) Touts Positive Asthma Drug Results From Two Phase 3 Studies 3/14/2014
CrystalGenomics Announces Positive Results Of Phase 3 Trial Of Polmacoxib (CG100649) In Patients With Osteoarthritis 3/13/2014
Novartis AG (NVS) Drug Jakavi® Gets Tagged As A Potential Blockbuster After Positive Late-Stage Study 3/10/2014
RedHill Biopharma Ltd. (RDHL) Provides Update On RHB-102 Development And Intellectual Property 3/7/2014
Genmab A/S (GEN.CO) Announces Phase 3 Study Of Daratumumab In Relapsed Or Refractory Multiple Myeloma 3/5/2014
LFB S.A. Initiates Global Phase 3 Clinical Trial Of New Coagulation Factor Viia (Recombinant) In Patients With Hemophilia A And B 3/3/2014
Actelion Ltd. (ALIOF.PK)'s Diarrhea Treatment Gets Fast-Track From The FDA 3/3/2014
Sinovac Biotech Ltd. (SVA)'s EV71 Vaccine Phase III Clinical Trial Results Published In The New England Journal of Medicine 2/27/2014
Shire plc Release:” New Phase 3 Data For Guanfacine Extended Release (GXR) To Be Presented At European Congress Of Psychiatry 2/27/2014
AB Science (AB.PA): Initiation Of A New Phase 3 Study With Masitinib In Prostate Cancer, Following Encouraging Survival Results Obtained In A Phase 2 Study 2/21/2014
Auris Medical AG Announces Enrollment Of First Patient In European Phase 3 Study Of AM-101 In Treatment Of Acute Peripheral Tinnitus 2/21/2014
AB Science (AB.PA): Initiation Of A New Phase 3 Study With Masitinib In Prostate Cancer, Following Encouraging Survival Results Obtained In A Phase 2 Study 2/20/2014
Active Biotech AB (BTPC) Release: Change In The Clinical Development Program For Laquinimod 2/19/2014
AstraZeneca PLC (AZN) Chases Demon Disease Cure, Potential To Be A Blockbuster Drug 2/17/2014
GlaxoSmithKline (GSK) Finally Starts Much-Anticipated Phase 3 Study For Rare Disease 2/17/2014
Merck & Co., Inc. (MRK) Joins Race To Copy Sanofi (France) (SAN.PA)'s Lantus 2/12/2014
Ipsen (IPN.PA) Says Phase 3 Prostate Cancer Drug Study Results Are Positive 2/7/2014
Shire plc Scraps Vyvanse® For Depression After Failed Phase 3 Trials 2/7/2014
Zealand Pharma  (ZEAL.CO) Informs That Sanofi (France) (SAN.PA) Has Announced Initiation Of The Lixilan Phase 3 Clinical Program For The Fixed-Ratio Combination Of Lantus® And Lyxumia® 2/6/2014
GlaxoSmithKline (GSK) Talks Up Its Pipeline 2/6/2014
Ipsen (IPN.PA) Announces Clinical Results Of Dysport® Next Generation (DNG) And Its Intent To File The First Ready-To-Use Liquid Toxin A In Europe And ROW1 2/5/2014
Medivation, Inc. (MDVN) Prevails Again As Prostate Cancer Drug Impresses In Pre-Chemo Study 1/30/2014
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO) To Present New Data On Brexpiprazole In Major Depression (MDD) At European Congress Of Psychiatry (EPA) 1/24/2014
Roche (RHHBY)'s Schizophrenia Drug, Bitopertin, Misses Goal In Two Late-Stage Trials 1/22/2014
ProSensa Holding N.V. (RNA) Reports Initial Findings From The Further Clinical Data Analyses Of Drisapersen For The Treatment Of Duchenne Muscular Dystrophy 1/16/2014
Zealand Pharma  (ZEAL.CO) Announces Advance By Sanofi (France) (SAN.PA) Of Lixilan, The Single Injection Lyxumia®/Lantus® Combination Product, Towards Phase 3 Development And A Related Milestone Payment 1/15/2014
Shield Therapeutics' ST10 Delivers Robust Results Meeting Both Primary And Secondary Endpoints In The Pivotal AEGIS Phase 3 Program For The Treatment Of Iron Deficiency Anemia In Inflammatory Bowel Disease 1/7/2014
ADImmune Corporation Plans To Sell Its Flu Vaccine In China This Year 1/7/2014
RedHill Biopharma Ltd. (RDHL) Provides Update On Pk Program In Support Of Ongoing Rhb-104 Phase 3 Crohn's Study 1/6/2014
TauRx Therapeutics Expands Alzheimer's Clinical Trials In The United States 1/6/2014
Takeda Pharmaceutical Co. Ltd. (TKPYY) Dealt A Huge Blow As Development Of Diabetes Drug Is Terminated 1/2/2014
OphthaliX Inc.'s Dry Eye Drug CF101 Fails To Meet Goals In Phase 3 Study 12/31/2013
Veloxis Pharmaceuticals A/S (VELO) Envarsus® Granted Orphan Drug Status By FDA For Kidney Transplant Rejection Prophylaxis 12/27/2013
RedHill Biopharma Ltd. (RDHL) Reports Positive PK Results In Support Of Ongoing RHB-105 Phase 3 H. Pylori Study 12/23/2013
ProSensa Holding N.V. (RNA) Comments On Drisapersen Program Update 12/20/2013
Onconova Therapeutics Inc. (ONTX) Tanks As Study Of Lead Pancreatic Drug Fails Phase 3 Trial; Stock Down -18.68% At Market Close (Dec. 18, 2013) 12/19/2013
Andromeda Biotech Announces First Patient Dosed In Extension Study To Its Phase 3 Clinical Trial DIA-AID 2 In Patients With Type 1 Diabetes 12/18/2013
Ipsen (IPN.PA) Announces Positive Initial Results From The International Double-Blind Clinical Phase III Study of Dysport® In The Treatment Of Adults Suffering From Upper Limb Spasticity 12/17/2013
RedHill Biopharma Ltd. (RDHL) Announces First Patients Dosed In Phase 3 Study Of RHB-105 For H. Pylori Infection 12/17/2013
FINOX Biotech Announces First Patients Enrolled In Pivotal US Phase III (FIN3002) Study For Rfsh 12/17/2013
AstraZeneca PLC (AZN) Announces Top-Line Results From Phase 3 Monotherapy Study Of Lesinurad In Gout Patients 12/16/2013
Hepatitis C: Phase 3 Data Show Boehringer Ingelheim Corporation's Faldaprevir* Is Effective Even In Patients With Common Drug-Resistant Viral Variant 12/16/2013
Kamada Ltd. (KMDA.TA) Announces Completion Of Pivotal Phase 2/3 Clinical Trial In Europe And Canada Of Inhaled AAT To Treat Alpha-1 Antitrypsin Deficiency 12/11/2013
Novartis AG (NVS) Bone Marrow Cancer Drug Wows In Late-Stage Study 12/9/2013
Phase 3 Data Show Daiichi Sankyo, Inc. (4568.t)'s Once-Daily Edoxaban Lowered Incidence Of VTE Recurrence And Clinically Relevant Bleeding Compared To Warfarin In A Large Subgroup Of Patients With Cancer 12/9/2013
Biogen Idec, Inc. (Massachusetts) (BIIB) And Swedish Orphan Biovitrum Release: New Phase 3 Data Confirm Long-Lasting Characteristics Of ALPROLIX™ And ELOCTATE™ Across Multiple Hemophilia Populations 12/9/2013
GlaxoSmithKline (GSK), Theravance, Inc. (THRX)'s Asthma Drug Improved Lung Function In Phase 3 Study 12/9/2013
Shire plc's New Eye Drug, Lifitegrast, Disappoints In Pivotal Trial 12/6/2013
BioAlliance Pharma Release: Approval To Start Relive (Livatag®) Phase III Clinical Trial In Primary Liver Cancer In The US And Germany 12/4/2013
New Phase 3 Data Backs Promise Of Sanofi (France) (SAN.PA)'s Long-Acting Insulin 12/4/2013
Novo Nordisk A/S (NVO)'s Ryzodeg® Offers Improved Glycemic Control With Significantly Lower Rates Of Hypoglycaemia Compared To Biphasic Insulin Aspart 30 In Adults With Type 2 Diabetes 12/3/2013
Swedish Orphan Biovitrum's Partner Biogen Idec, Inc. (Massachusetts) (BIIB) To Present Phase 3 Data On Prolonged Half-Life Of Hemophilia Candidates In Young Children At Annual American Society of Hematology Meeting 12/3/2013
Basilea Pharmaceutica (BSLN.SW) Reports That Isavuconazole Receives Qualified Infectious Disease Product (QIDP) Designation From U.S. FDA For The Treatment Of Invasive Aspergillosis 12/3/2013
AB Science (AB.PA) Announces Initiation Of A New Phase 3 Study In Oncology With Masitinib In Patients With Metastatic Colorectal Cancer 12/3/2013
RedHill Biopharma Ltd. (RDHL) Announces First Patient Dosed In Phase 3 Study Of RHB-104 For Crohn's Disease 11/25/2013
Novartis AG (NVS) Chases Pfizer Inc. (PFE) In Hot New Breast Cancer Drug Area 11/25/2013
Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Arthritis Drug Meets Goals In Phase 3 Study 11/22/2013
Basilea Pharmaceutica (BSLN.SW) Reports Isavuconazole Orphan Drug Designation For Treatment Of Zygomycosis By FDA 11/18/2013
GW Pharmaceuticals Provides Update On Orphan Program In Childhood Epilepsy For Epidiolex® 11/15/2013
Biogen Idec, Inc. (Massachusetts) (BIIB) and Swedish Orphan Biovitrum Release: Leading Hematology Journal Publishes Pivotal Eloctate Tm Data That Demonstrated Efficacy And Safety Of Investigational Long-Lasting Therapy For Hemophilia A 11/13/2013
GlaxoSmithKline (GSK) Heart Drug Misses Goal In Major Study 11/13/2013
AB Science (AB.PA): Final Results Of Phase 3 Mastocytosis Study Expected By End Of 2014 11/12/2013
Clinuvel Successful In U.S. Phase III Trial Of SCENESSE® In Rare Skin Disorder 11/11/2013
AB Science (AB.PA): Masitinib Successfully Passes Futility Analysis in Pivotal Clinical Study in Mastocytosis 11/11/2013
ALK-Abello A/S's Partner In North America, Merck & Co. (Westpoint, PA) (MRK), Reports Phase III Data On Investigational Grass Sublingual Allergy Immunotherapy Tablet 11/11/2013
Pharming Group (PHGUF.PK) and Santarus Inc. (SNTS) Announce New Data From Open-Label Repeat Treatment Study With Rucomest 11/8/2013
Genentech (RHHBY)'s Gazyva Extends Leukemia Patients’ Survival 11/7/2013
ProSensa Holding N.V. (RNA) Enrolls 100th Patient to its Natural History Study of Duchenne Muscular Dystrophy 11/7/2013
Bone Therapeutics' Pivotal Phase III Osteonecrosis Trial With PREOB® hits a New Milestone 11/7/2013
Shire plc's ADHD Drug Succeeds in Phase 3 Trial to Treat Binge Eating 11/5/2013
Auris Medical AG Reaches Special Protocol Assessment Agreement With FDA for Pivotal Phase III Clinical Trial With AM-101 in Treatment of Acute Peripheral Tinnitus 11/4/2013
Medivir AB (MVRBF) Announces That New Simeprevir Data Will be Presented at the American Association for Study of Liver Diseases Meeting 11/4/2013
FDA Clears Commencement of Phase 3 Chronic Heart Failure Trial Using Mesoblast Limited (MSB.AX)'s Proprietary Cells 10/31/2013
RedHill Biopharma Ltd. (RDHL) Initiates Phase III Study of RHB-105 for H. pylori Infection 10/30/2013
Boehringer Ingelheim Corporation Release: New Data show Striverdi® (olodaterol)* Respimat® Improves Exercise Tolerance in Patients With Moderate to Very Severe COPD1 10/29/2013
Roche (RHHBY)'s Investigational Roactemra Subcutaneous Formulation Shows Comparable Long-Term Efficacy and Tolerability to the Intravenous Formulation in Rheumatoid Arthritis 10/28/2013
BioAlliance Pharma Announces Third Positive DSMB Recommendation to Continue Its Phase III Clinical Trial With Livatag® in Primary Liver Cancer 10/22/2013
vasopharm BIOTECH GmbH Reports Endorsement of Phase III Trial Design in Traumatic Brain Injury by European Medicines Agency 10/22/2013
Medivir AB (MVIRb.F) Announces Data From Two Phase 3 Studies With Simeprevir in Hepatitis C Subpopulations – HCV/HIV Co-Infected and Genotype 4 Infected Patients 10/18/2013
Celgene International Sárl (CELG) Release: ABRAXANE® Phase III Study of Patients With Metastatic Pancreatic Cancer Published in The New England Journal of Medicine 10/17/2013
Gilead Sciences, Inc. (GILD)'s Single Tablet HIV Regimen Stribild® Demonstrates Durable Viral Suppression Through Three Years of Therapy 10/16/2013
RedHill Biopharma Ltd. (RDHL)'s RHB-104 Combination Achieves 80% Remission in Independent Pediatric Crohn's Study 10/15/2013
This Slide Paints Grim Picture of GlaxoSmithKline (GSK), ProSensa Holding N.V. (RNA)'s DMD Drug 10/11/2013
Lundbeck Inc. (LUN.CO) and Otsuka Pharmaceutical Co., Ltd. Initiate Phase 3 Clinical Trials on Lu AE58054 as a New Add-on Treatment for Alzheimer's Disease 10/10/2013
AOP Orphan Pharmaceuticals AG Announces Progress of Pivotal Phase III Trial PROUD-PV of Novel Mono-Pegylated Interferon Alpha 2b for the Treatment of Polycythemia Vera 10/10/2013
Alkermes plc (ALKS) Receives Fast Track Designation for ALKS 5461 for Major Depressive Disorder 10/10/2013
RedHill Biopharma Ltd. (RDHL) Reports Positive PK Clinical Studies Towards Planned NDA with RHB-102 (Anti-Emetic) 10/8/2013
Novartis AG (NVS)'s Omalizumab Shines in Third Phase 3 Hives Trial 10/8/2013
Novartis AG (NVS)'s Secukinumab Set to Challenge Amgen (AMGN), Pfizer Inc. (PFE)'S Enbrel® 10/7/2013
Medivir AB (MVIRb.F) Release: Simeprevir Data From COSMOS Study in Hepatitis C Patients Will be Presented as Late-Breaking Presentation at American Association for Study of Liver Diseases 10/7/2013
Celgene International Sárl (CELG) Release: Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study 10/3/2013
Roche (RHHBY) Updates Late-Stage Pipeline; Highlights Drugs Outside Core Cancer Focus 10/2/2013
Active Biotech AB (BTPC) and Teva Pharmaceutical Industries Limited (TEVA) Release: Newly Published Phase 3 Exploratory Analysis Suggests Investigational Oral Laquinimod for Multiple Sclerosis May Reduce Brain Damage Caused by Neurodegeneration 10/1/2013
RedHill Biopharma Ltd. (RDHL) Initiates Phase III Study of RHB-104 for Crohn's Disease 10/1/2013
Ipsen (IPN.PA): Results From CLARINET® Phase3 Clinical Trial Showed the Antiproliferative Effect of Somatuline® in the Treatment of Non-Functioning GEP-NETs 9/30/2013
Merck Serono's Erbitux Significantly Extends Survival by 7.5 Months in mCRC RAS Wild-Type Patients When Compared With Bevacizumab: New Analysis of FIRE-3 AIO Study 9/30/2013
Boehringer Ingelheim Corporation Release: Nintedanib Extended Survival Beyond One Year for Advanced Adenocarcinoma Patients After Prior First-Line Chemotherapy 9/30/2013
Astellas Pharma Inc. (ALPMY) Reports Positive Topline Phase 3 Results for Antifungal Isavuconazole 9/30/2013
Sanofi (France) (SAN.PA) Cholesterol Drug Touted as Potential $3 Billion Blockbuster 9/27/2013
Eli Lilly and Company (LLY) Reports Positive Patient-Reported Health Outcomes From Phase 3 Dulaglutide Trial 9/26/2013
Amarin Corporation PLC (AMRN) Announces Enrollment of the REDUCE-IT Cardiovascular Outcomes Study Surpasses 6,000 Patients 9/25/2013
Zealand Pharma  (ZEAL.CO) Informs That Data Presented on Lyxumia® Support Known Complementary Effects of This Diabetes Medicine in Combination With Basal Insulin 9/24/2013
GlaxoSmithKline (GSK), ProSensa Holding N.V. (RNA)'s Muscular Dystrophy Drug Fails in Phase 3 Trial; ProSensa Stock Plunges -70.25% at Market Close on September 20, 2013 9/23/2013
FDA Grants Breakthrough Status for GlaxoSmithKline (GSK), Genmab A/S (GEN.CO)'s Arzerra®; Genmab Stock Soars +9.94% at Market Close (September 16, 2013) 9/17/2013